Vertex Pharmaceuticals Incorporated (VRTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, VRTX scores 80 out of 100, a letter grade of B+, labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The five pillars are:

• Fundamental Cash Engine: 17 / 20. Per the RQD rating, this reflects ROIC of 20% and an FCF yield of 2.33%. For a prospective investor, the high return on capital is the strongest support in this pillar, while the 2.33% FCF yield signals that the cash generated is large relative to the share price only modestly; valuation, not operating quality, is the main tradeoff.
• Whale 13F Flow: 17 / 20. Per the RQD rating, this pillar captures institutional accumulation and options positioning. The underlying 13F detail is not itemized in the source data, so the score can be read as a signal of supportive institutional sentiment, but its drivers cannot be verified here.
• Insider Conviction: 15 / 20. Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The individual transactions are not itemized in the source data, so the score indicates a moderately positive insider read without specifying direction or magnitude.
• Macro Regime Fit: 15 / 20. Per the RQD rating, this reflects a beta of 1.02 and sector sensitivity. A beta near 1.0 means the stock has tended to move roughly in line with the broad market, so it offers neither a defensive cushion nor a high-volatility amplifier.
• Forensic Balance Sheet: 16 / 20. Per the RQD rating, this reflects Altman Z 13.86, Piotroski F 8/9, and Debt/Equity 0.16. These are strong readings, indicating low financial distress risk and a conservatively levered balance sheet.

Taken together, the rating points to a high-quality, cash-generative franchise with strong institutional and insider signals, offset by a premium valuation (P/E TTM 34.6) that limits the margin of safety for new buyers. Upside drivers are the high ROIC and balance-sheet strength; the main valuation tradeoff is the elevated multiple relative to the 2.33% FCF yield.

Per the SEC financials, revenue grew from $9869.2M (FY 2023) to $12001.3M (FY 2025), with FY 2025 returning to operating income of $4173.3M and net income of $3953.2M after a loss-making FY 2024. Per the market data, operating margin is 34.8% and net margin is 32.9%, with ROIC of 20%. The source data reports an Altman Z-Score of 13.86 and a Piotroski F-Score of 8/9 (per the RQD rating), both pointing to strong financial health. Debt/Equity is 0.16 per the RQD rating, and FY 2025 debt of $3139.7M sits against cash of $5084.8M. Reported EPS is N/A for all periods in the financials table.

Per the recent news feed, the flow of coverage is dominated by market-attention and analysis pieces, all marked YELLOW. Specific items include:

• A forthcoming earnings event: Vertex announced it would report third-quarter 2026 financial results on November 2nd, which aligns with the data as-of date.
• A scientific presentation at the American Society of Nephrology Kidney Week 2026 (dated 2026-10-23).
• Multiple market-wire pieces on investor interest and stock forecasts, which are general commentary rather than discrete company events.

Risk watch items are not specifically itemized in the source data. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

• What are the specific products, indications, and revenue drivers behind the FY 2025 revenue of $12001.3M?
• Why is reported EPS N/A across all periods, and what is the share count underlying the EPS (TTM) of 15.6?
• What drove the FY 2024 net loss of $-535.6M, and does the swing to $3953.2M net income in FY 2025 reflect recurring operations?
• The FY 2023 cash field is N/A and debt is $17615.0M; what is the balance-sheet trajectory between FY 2023 and FY 2025?
• What are the specific insider, 13F, and options-positioning transactions underlying the RQD flow pillars?